Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients… Click to show full abstract
Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated to decrease cardiovascular adverse events. However, there is little real‐world clinical evidence regarding a direct comparison between dapagliflozin and empagliflozin in patients with diabetes mellitus (DM).
Keywords:
patients diabetes;
diabetes mellitus;
outcomes dapagliflozin;
cardiovascular outcomes;
empagliflozin patients
Journal Title: Clinical Cardiology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cardiology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!